Security key
761330109
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)
CUSIP: 761330109
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 173,355
- Total 13F value
- $899,713
- Share change
- +173,355
- SEC-reported price per share
- $5.19
- Number of holders
- 1
- Value change
- +$899,713
- Number of buys
- 1
- Shares outstanding
- 104,661,494
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
1
Top holders
0
RVNC full security history
Ownership snapshot
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Revance Therapeutics, Inc. SEC filings
Revance Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 761330109
Recent filing periods:
Ownership snapshot
Top reported holders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Teoxane SA
Disclosed value leader
Teoxane SA
Comparable rows
3/14
Latest evidence
04 Feb 2025
13D/G
3/4/5
Lead comparable stake: 6.2%
11 rows are not safely comparable across share classes.
13D/G row: Teoxane SA
Showing 1-6 of 14 holder rows.
Quick read
Teoxane SA leads the comparable SEC ownership view at 6.2%.
3 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Teoxane SA's linked filing trail.
Comparable ownership
Top 3
Teoxane SA
6.2%
FRANKLIN RESOURCES INC
4.6%
Palo Alto Investors LP
1.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Teoxane SA |
13D/G
|
6.2%
|
$32,335,404
6,550,800 shares
|
$0 | 30 Jan 2025 |
| FRANKLIN RESOURCES INC |
13D/G
|
4.6%
|
$23,617,550
4,784,658 shares
|
$0 | 30 Sep 2024 |
| Palo Alto Investors LP |
13D/G
Patrick Lee, MD
|
1.5%
|
$7,955,942
1,611,787 shares
|
$0 | 30 Sep 2024 |
| Aubrey Rankin |
3/4/5
Director
|
—
class O/S missing
|
$4,257,930
570,004 shares
|
— | 15 Mar 2022 |
| Abhay Joshi |
3/4/5
COO, President of R&D
|
—
class O/S missing
|
$901,689
120,708 shares
|
— | 15 Mar 2022 |
| Dustin S. Sjuts |
3/4/5
President
|
—
class O/S missing
|
$844,871
167,550 shares
|
— | 15 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Archived quarter
Historical 13F summary for Q3 2025
This older quarter remains available as an indexed ownership summary. Detailed holder rows are no longer kept in the hot table for this period.